Skip to main content
Equibles
TNXP logo

TNXP · Tonix Pharmaceuticals Holding Corp.

Track TNXP — free

Use TNXP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$13.14 -0.23 (-1.72%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 10, 2026
Market Cap
$225.36M
Shares
17.15M

TNXP metrics

67 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$13.14
Market cap
$225.36M

Price action

19 metrics
Price change (1W)
-3.3%
Price change (30D)
+4.4%
Price change (3M)
+18.7%
Price change (6M)
-2.3%
Price change (YTD)
-15.9%
Price change (1Y)
-50.1%
Trailing year
Price change (5Y)
—
52-week high
$31.21
52-week low
$9.51
Change from 52-week high
-57.9%
Change from 52-week low
+38.2%
Annualized volatility
72.8%
Beta
2.2
RSI (14D)
54.9
Price vs SMA 50
+8.4%
Price vs SMA 200
-6.9%
Avg volume (3M)
525,376
Relative volume
0.5
Average dollar volume
$6.32M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
17.15M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
7.7×
reciprocal yield 12.9%
P / book
1.0
reciprocal yield 98.6%
FCF yield
-70.2%
TTM · current market cap
Buyback yield
6.1%
P / FCF
—
P / operating cash flow
—
Earnings yield
-70.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
10.1×
reciprocal yield 9.9%
EV / revenue historical average (5Y)
10.1×
reciprocal yield 9.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
6.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
83.8%
Operating margin
-568.4%
Trailing 12 months
Net margin
-548.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$165.43M
Net income (TTM)
−$159.67M
Trailing 12 months
Diluted EPS (TTM)
$-13.24
FCF margin
-543.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-1,749.53

Growth

11 metrics
Revenue growth YoY
+577.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$29.10M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+127.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-71.8%
Return on assets
-62.8%
Debt / equity
—
Current ratio
6.6
EBITDA (TTM)
−$163.34M
Free cash flow (TTM)
−$158.11M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$176.23M
Total assets
$254.09M
Total debt
$7.49M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$152.99M
Capital expenditures (TTM)
$5.12M
R&D (TTM)
$63.86M
SG&A (TTM)
$125.96M
Stock compensation (TTM)
$7.94M
R&D / revenue
219.4%
Stock compensation / revenue
27.3%

Ownership (13F)

3 metrics
13F filers
104
13F filer change QoQ
+22
Institutional ownership
57.3%

Short interest

3 metrics
Short interest
19.9%
Latest settlement · 7.0 days to cover
Days to cover
7.0d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
$114,058
Insider-sentiment score
87 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1430306 CUSIP 890260839 13F (30d) 72 filings 72 filers Visit website Investor relations